- Home
- ANEB vs ICCC Comparison
ANEB vs ICCC Comparison
Compare ANEB & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- ICCC
- Stock Information
- Founded
- ANEB 2020
- ICCC 1982
- Country
- ANEB United States
- ICCC United States
- Employees
- ANEB N/A
- ICCC N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- ICCC Health Care
- Exchange
- ANEB Nasdaq
- ICCC Nasdaq
- Market Cap
- ANEB 39.0M
- ICCC 46.2M
- IPO Year
- ANEB 2021
- ICCC 1987
- Fundamental
- Price
- ANEB $1.06
- ICCC $6.78
- Analyst Decision
- ANEB Strong Buy
- ICCC
- Analyst Count
- ANEB 2
- ICCC 0
- Target Price
- ANEB $5.50
- ICCC N/A
- AVG Volume (30 Days)
- ANEB 11.6K
- ICCC 27.2K
- Earning Date
- ANEB 05-13-2025
- ICCC 05-14-2025
- Dividend Yield
- ANEB N/A
- ICCC N/A
- EPS Growth
- ANEB N/A
- ICCC N/A
- EPS
- ANEB N/A
- ICCC N/A
- Revenue
- ANEB N/A
- ICCC $27,302,766.00
- Revenue This Year
- ANEB N/A
- ICCC N/A
- Revenue Next Year
- ANEB N/A
- ICCC N/A
- P/E Ratio
- ANEB N/A
- ICCC N/A
- Revenue Growth
- ANEB N/A
- ICCC 28.29
- 52 Week Low
- ANEB $0.80
- ICCC $3.34
- 52 Week High
- ANEB $3.08
- ICCC $6.95
- Technical
- Relative Strength Index (RSI)
- ANEB 47.21
- ICCC 74.35
- Support Level
- ANEB $1.00
- ICCC $6.00
- Resistance Level
- ANEB $1.15
- ICCC $6.72
- Average True Range (ATR)
- ANEB 0.07
- ICCC 0.42
- MACD
- ANEB 0.01
- ICCC 0.11
- Stochastic Oscillator
- ANEB 44.49
- ICCC 92.17
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.